ABOUT US

NELUM IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING BEST IN CLASS PATENTED MOLECULES WITH A FOCUS ON UNMET CLINICAL NEEDS. OUR AREAS OF FOCUS ARE FIBROSIS AND DIFFERENT FORMS OF CANCER.

OUR FIRST DRUG, NLM-001, IS A BEST IN CLASS SMALL MOLECULE HEDGEHOG INHIBITOR INLICENSED FROM TAKEDA AND PREVIOUSLY KNOWN AS TAK-441.

THE COMPOUND IS CURRENTLY IN a PHASE IB-IIA CLINICAL TRIAL IN PANCREATIC CANCER, AFTER SHOWING A SAFE PROFILE IN THE PHASE I.

NLM-001 IS ALSO BEING STUDIED IN FIBROTIC CONDITIONS SUCH AS PULMONARY, LIVER OR SKIN FIBROSIS.